Ex-Citi analyst Andrew Baum has left his role as chief strategy and innovation officer at Pfizer, but he will be a senior strategic advisor to CEO Albert Bourla.
→ Ex-Citi analyst Andrew Baum has left his role as chief strategy and innovation officer at Pfizer, but he will be a senior strategic advisor …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Boehringer Ingelheim has brought in Christie Bloomquist as SVP, corporate affairs, US human pharma, and she’ll be president of…
With the ink barely dry on outgoing commissioner Marty Makary’s resignation, another top regulator may be heading for the exit at…
With the FDA now rudderless following the revelation that commissioner Marty Makary, M.D., is stepping down, voices across…
Pfizer made one thing clear this week: It's officially back in the obesity race.
Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson.
They called for stability and predictability at the agency at Axios' Future of Health summit.
